1.MOLECULAR IDENTIFICATION AND CLASSIFICATION OF DEEP SEA PSYCHROPHILIC BACTERIA FROM EAST-PACIFIC SEDIMENT
Microbiology 1992;0(06):-
Many psychrophilic bacteria were isolated from east-pacific sediment which is 5,300m in depth. The genera of 13 isolations were identified and classified based on the comparison and phylogenetic study of 16S rRNA gene sequences. The results indicated that they belong to four genera including Parococcus, Pseudomonas, Halomonas and Pseudoalteromonas.
2.Recent progress in targeting degradation of FAK based on PROTAC
Ying-ruo XU ; Qin-song ZHANG ; Jing-yi WU ; Run-fei BAO ; Shen-xin ZENG
Acta Pharmaceutica Sinica 2021;56(6):1571-1579
Local focal adhesion kinase (FAK) is a non-receptor intracellular tyrosine kinase that plays an important role in tumor initiation, development, metastasis and invasion, and is considered to be an important target for the development of antineoplastic drugs. It has both kinase-dependent and non-kinase-dependent scaffolding functions. However, traditional small molecular inhibitors can only inhibit its kinase-dependent activity, so it is difficult to target the kinase-independent scaffolding function. Therefore, there is an urgent need for novel strategies to enhance FAK targeting to lay the foundation for determining the druggability and discovery of FAK inhibitors. Proteolysis targeting chimera (PROTAC) is a new drug development strategy that can recruit E3 ligase to specifically ubiquitinylate target proteins for degradation through the proteasome system. The unique mechanism of action of the PROTAC system could be used to target and degrade the FAK protein, thus eliminating the scaffolding function of FAK. In this review, FAK protein, the signaling pathway, and small molecule inhibitors are briefly described, and the latest research progress in targeting the degradation of FAK using PROTAC technology is summarized.
3.A sequence investigation on Wallerian degeneration after pontine infarction with diffusion tensor imaging
Zhi-Jian LIANG ; Si-Run LIU ; Jin-Sheng ZENG ; An-Ding XU ; Xue-Ying LING ; Fang WANG ; Li LING ; Qing-Hua HOU ; Shi-Hui XING ;
Chinese Journal of Neurology 2005;0(11):-
Objective To investigate the Wallerian degeneration of neural fiber tract in medulla and bilateral middle cerebellar peduncle following pontine infarction and to explore its impacts on neurological recovery.Methods Fourteen patients with a recent unilateral pontine infarct underwent the diffusion tensor imaging(DTI)and evaluations with the NIH stroke scale(NIHSS),the Fugl-Meyer motor scale(FM), ataxia rating scale(ARS)and the Barthel index(BI)at the first week(W1),the fourth(W4)and twelfth week(W12)respectively.Mean diffusivity(MD)and fractional anisotropy(FA)were measured at pons, medulla and middle cerebellar peduncle.Fourteenth age and gender matched volunteers underwent a DTI were studied as controls.Results Compared with the matched regions in controls,the FA values of infarct side medulla and bilateral middle cerebellar peduncle in patients significantly decreased at W1,W4 and W12(on the infarct side of medulla:W1:0.43?0.01;W4:0.37?0.02;W12:0.30?0.02;on the infarct side of middle cerebellar peduncle:W1:0.50?0.01;W4:0.43?0.02;W12:0.35?0.04;on the opposite side of middle cerebellar peduncle infarction:W1:0.54?0.02;W4:0.52?0.03;W12:0.47?0.04,t values are 1.92 to 28.56,P0.05 respectively).The absolute value of percent reduction of FA in infarct side medulla and bilateral middle cerebellar peduncle was correlated negatively to the absolute value of percent change of NIHSS and BI score(P
4.Clinical and genetic analyses of juvenile myelomonocytic leukemia.
Min-Hui ZENG ; Xiang-Ling HE ; Ming-Hua YANG ; Min-Cui ZHENG ; Wu-Qing WAN ; Run-Ying ZOU ; Ke-Ke CHEN
Chinese Journal of Contemporary Pediatrics 2019;21(4):365-369
OBJECTIVE:
To study the clinical and genetic features of juvenile myelomonocytic leukemia (JMML) and the association between genotype and prognosis. Methods The clinical data of 15 children who were diagnosed with JMML were collected. Next-generation sequencing was used to detect common gene mutations of JMML.
RESULTS:
The male/female ratio was 6.5:1, and the age of onset was 19 months (range 2-67 months). Of the 15 children, 11 (73%) experienced disease onset before the age of 4 years, with abdominal distension and pyrexia as initial symptoms. All children had hepatosplenomegaly and superficial lymphadenectasis, with a number of peripheral blood mononuclear cells of >1.0×10/L and a percentage of juvenile cells of 1%-7% in peripheral blood smear. The percentage of bone marrow blasts + juvenile cells was <20%, and the percentage of monoblasts + promonocytes was 1%-10%. Of the 15 children, 10 (67%) had a higher level of hemoglobin F than the normal level at the corresponding age, with the highest level of 62.5%. All 15 children had the absence of Philadelphia chromosome, and one child had chromosome 7 deletion. All 15 children had a negative result of BCR/ABL fusion gene detection. PTPN11 gene mutation was found in 5 children (33%), NF1 mutation in 4 children (27%), CBL mutation in 3 children (20%), and RAS mutation in 3 children (20%). No children received regular chemotherapy, and one child underwent hematopoietic stem cell transplantation. The median follow-up time of 15 children was 18 months (range 1-48 months). Among the 15 children, 8 died (among whom 4 had PTPN11 gene mutation, 3 had NF1 mutation, and 1 had RAS mutation) and 7 survived. The children with PTPN11 mutation had the worst prognosis and the highest mortality rate, and those with CBL or NRAS mutation had a relatively good prognosis. The level of hemoglobin F was negatively correlated with survival time (r=-7.21, P=0.002).
CONCLUSIONS
In children with JMML, the type of gene mutation is associated with prognosis. The children with PTPN11 mutation often have a poor prognosis, and those with CBL or NRAS mutation have a relatively good prognosis.
Adolescent
;
Child
;
Female
;
Hematopoietic Stem Cell Transplantation
;
Humans
;
Leukemia, Myelomonocytic, Juvenile
;
genetics
;
Leukocytes, Mononuclear
;
Male
;
Mutation
;
Prognosis
5.Clinical effect of multicenter multidisciplinary treatment in children with renal malignant tumors.
Ze-Xi YIN ; Xiang-Ling HE ; Jun HE ; Xin TIAN ; Cheng-Guang ZHU ; Ke-Ke CHEN ; Run-Ying ZOU ; Ya-Lan YOU ; Xin-Ping JIANG ; Wen-Fang TANG ; Min-Hui ZENG ; Zhi-Jun HUANG ; An-Qi YAO
Chinese Journal of Contemporary Pediatrics 2021;23(2):169-173
OBJECTIVE:
To study the long-term clinical effect of multicenter multidisciplinary treatment (MDT) in children with renal malignant tumors.
METHODS:
A retrospective analysis was performed on the medical data of 55 children with renal malignant tumors who were diagnosed and treated with MDT in 3 hospitals in Hunan Province from January 2015 to January 2020, with GD-WT-2010 and CCCG-WT-2016 for treatment regimens. A Kaplan-Meier survival analysis was used to analyze the survival of the children.
RESULTS:
Of the 55 children, 10 had stage I tumor, 14 had stage Ⅱ tumor, 22 had stage Ⅲ tumor, 7 had stage IV tumor, and 2 had stage V tumor. As for pathological type, 47 had FH type and 8 had UFH type. All children underwent complete tumor resection. Of the 55 children, 14 (25%) received preoperative chemotherapy. All children, except 1 child with renal cell carcinoma, received postoperative chemotherapy. Among the 31 children with indication for radiotherapy, 21 (68%) received postoperative radiotherapy. One child died of postoperative metastasis. The incidence rate of FH-type myelosuppression was 94.4%, and the incidence rate of UFH-type myelosuppression was 100%. The median follow-up time was 21 months and the median survival time was 26 months for all children, with an overall survival rate of 98% and an event-free survival rate of 95%.
CONCLUSIONS
Multicenter MDT has the advantages of high success rate of operation and good therapeutic effect of chemotherapy in the treatment of children with renal malignant tumors, with myelosuppression as the most common side effects, and radiotherapy is safe and effective with few adverse events. Therefore, MDT has good feasibility, safety, and economy.
Child
;
Family
;
Humans
;
Kidney Neoplasms/therapy*
;
Progression-Free Survival
;
Retrospective Studies
6.Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
Binghe XU ; Qingyuan ZHANG ; Xichun HU ; Qing LI ; Tao SUN ; Wei LI ; Quchang OUYANG ; Jingfen WANG ; Zhongsheng TONG ; Min YAN ; Huiping LI ; Xiaohua ZENG ; Changping SHAN ; Xian WANG ; Xi YAN ; Jian ZHANG ; Yue ZHANG ; Jiani WANG ; Liang ZHANG ; Ying LIN ; Jifeng FENG ; Qianjun CHEN ; Jian HUANG ; Lu ZHANG ; Lisong YANG ; Ying TIAN ; Hongyan SHANG
Acta Pharmaceutica Sinica B 2023;13(5):2250-2258
Entinostat plus exemestane in hormone receptor-positive (HR+) advanced breast cancer (ABC) previously showed encouraging outcomes. This multicenter phase 3 trial evaluated the efficacy and safety of entinostat plus exemestane in Chinese patients with HR + ABC that relapsed/progressed after ≥1 endocrine therapy. Patients were randomized (2:1) to oral exemestane 25 mg/day plus entinostat (n = 235) or placebo (n = 119) 5 mg/week in 28-day cycles. The primary endpoint was the independent radiographic committee (IRC)-assessed progression-free survival (PFS). The median age was 52 (range, 28-75) years and 222 (62.7%) patients were postmenopausal. CDK4/6 inhibitors and fulvestrant were previously used in 23 (6.5%) and 92 (26.0%) patients, respectively. The baseline characteristics were comparable between the entinostat and placebo groups. The median PFS was 6.32 (95% CI, 5.30-9.11) and 3.72 (95% CI, 1.91-5.49) months in the entinostat and placebo groups (HR, 0.76; 95% CI, 0.58-0.98; P = 0.046), respectively. Grade ≥3 adverse events (AEs) occurred in 154 (65.5%) patients in the entinostat group versus 23 (19.3%) in the placebo group, and the most common grade ≥3 treatment-related AEs were neutropenia [103 (43.8%)], thrombocytopenia [20 (8.5%)], and leucopenia [15 (6.4%)]. Entinostat plus exemestane significantly improved PFS compared with exemestane, with generally manageable toxicities in HR + ABC (ClinicalTrials.gov #NCT03538171).
7.Efficacy Analysis of MAC Regimen as Salvage Treatment Protocol for Acute Myeloid Leukemia Patients Older Than 55 Years.
Xing-Li ZHAO ; Shu-Ning WEI ; Kai-Qi LIU ; Dong LIN ; Hui WEI ; Ying WANG ; Chun-Lin ZHOU ; Bing-Cheng LIU ; Wei LI ; Zeng CAO ; Ben-Fa GONG ; Yun-Tao LIU ; Xiao-Yuan GONG ; Yan LI ; Run-Xia GU ; Guang-Ji ZHANG ; Jian-Xiang WANG ; Ying-Chang MI
Journal of Experimental Hematology 2015;23(2):396-400
OBJECTIVETo evaluate the efficacy and safety of MAC regimen in the treatment of acute myeloid leukemia(AML) patients older than 55 years.
METHODSA total of 33 relapsed or non-remission AML patients older than 55 years were enrolled in this research. MAC regimen was given as the salvage treatment. Complete remission rate(CR), partial remission rate(PR), overall survival(OS), relapse-free survival(RFS) and adverse effect were analysed.
RESULTSCR rate after the salvage therapy with MAC was 51.1%, partial remission (PR) rate was 6.1%, the overall response rate (ORR) was 57.6%, the median OS was 8 months (1.0-66.0 months), the median relapse-free survival (RFS) was 10.1 months (2.3-40.4 months). Mortality related with salvage treatment in 30 days was 9.1%. Low incidence of severe organ damage were found.
CONCLUSIONMAC can be used as a relative effective and safe regimen for the salvage treatment of the older AML patients.
Antineoplastic Combined Chemotherapy Protocols ; Chlorambucil ; Cytarabine ; Dactinomycin ; Humans ; Leukemia, Myeloid, Acute ; Methotrexate ; Middle Aged ; Recurrence ; Remission Induction ; Salvage Therapy
8.Characteristics of karyotypes and gene mutations for elder acute myeloid leukemia.
Xing-Li ZHAO ; Kai-Qi LIU ; Dong LIN ; Hui WEI ; Ying WANG ; Chun-Lin ZHOU ; Bing-Cheng LIU ; Wei LI ; Cheng-Wen LI ; Qing-Hua LI ; Zeng CAO ; Ben-Fa GONG ; Yun-Tao LIU ; Xiao-Yuan GONG ; Yan LI ; Run-Xia GU ; Ying-Chang MI ; Jian-Xiang WANG
Journal of Experimental Hematology 2015;23(2):300-305
OBJECTIVETo investigate the incidence of karyotypes and gene mutations for elder acute myeloid leukemia and to explore the relationship between each other.
METHODSClinical data and bone marrow samples of elder AML patients were collected. Karyotype and gene mutation (FLT3, NPM1, C-Kit, CEBPα, DNMT3A) test were performed, characteristics of karyotypes and gene mutations were analysed.
RESULTSThe incidence of better risk karyotype was 16.6%, in which the incidences of t(15;17), t(8;21) and inv (16)/t(16;16) were 3.90%, 10.73%, and 1.95% respectively; the incidence of intermediate risk karyotype was 72.2%, in which the incidence of normal karyotype was 57.86%; the incidence of poor risk karyotype was 11.20%, in which the incidence of of MLL/11q23, complex karyotype and monosomal karyotype were 1.95%, 6.34%, 5.85% respectively; the incidences of FLT3, NPM1, C-Kit, CEBPα, DNMT3A mutation were 12.57%, 22.06%, 2.16%, 14.71%, 15.71% respectively. Compared with patients older than 60 years, patients with age of 55-60 years were with less complex karyotype (1.09% vs 10.62%)(P=0.003) and monosomal karyotype (2.17% vs 8.85%)(P=0.032), and more t(8;21)(17.39% vs 5.31%)(P=0.008) and inv (16)/t(16;16)(4.35% vs 0.00%)(P=0.045).
CONCLUSIONFor older AML patients, great difference in the distribution of karyotyes was found between the patients older than 60 years and patients with age of 55-60 years, while no such characteristics was found for gene mutations. Good elucidation of karyotypes and gene mutations are key for the treatment of older acute myeloid leukemia patients.
Humans ; Incidence ; Karyotype ; Karyotyping ; Middle Aged ; Mutation ; Proto-Oncogene Proteins c-kit
9.Quality Control of Dynamic Volatile Components in Lonicerae Japonicae Flos and Lonicerae Flos
Hai-ying LI ; Qi-meng FAN ; Yu-ting HE ; Peng HE ; Min-cun WANG ; Run-nan LIU ; Zhuo ZHOU ; Xue-bing QIAN ; Xian-ping ZENG ; Mei-feng XIAO ; Fu-yuan HE
Chinese Journal of Experimental Traditional Medical Formulae 2020;26(22):148-155
Objective:The molecular connectivity index method and total statistical moment method were used to control the quality of traditional Chinese medicine (TCM), and the stability and consistency of volatile components of Lonicerae Japonicae Flos and Lonicerae Flos were clarified. Method:Volatile oils in Lonicerae Japonicae Flos and Lonicerae Flos from different producing areas was extracted for GC-MS determination with electron bombardment ion source, ion source temperature of 230 ℃, and detection range of